Evidence map›Paper›PMID 41754793›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Yin-Dan-Ping-Gan Capsule Mitigates CCL

Xue Jiang, Jicheng Yang, Yusheng Zhang, Ying Zhang, Zhen Ouyang, Chen Zhao, Limin Lin, Xianyu Li, Luqi Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xue JiangSchool of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China.ORCID 0000-0002-0102-7411
Jicheng YangBeijing Key Laboratory of China Academy of Chinese Medical Sciences on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Yusheng ZhangBeijing Key Laboratory of China Academy of Chinese Medical Sciences on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Ying ZhangBeijing Key Laboratory of China Academy of Chinese Medical Sciences on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Zhen OuyangSchool of Food and Biological Engineering, Jiangsu University, Zhenjiang 212013, China.
Chen ZhaoFujian Pien Tze Huang Enterprise Key Laboratory of Natural Medicine Research and Development, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., Zhangzhou 363000, China.
Limin LinFujian Pien Tze Huang Enterprise Key Laboratory of Natural Medicine Research and Development, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., Zhangzhou 363000, China.
Xianyu LiBeijing Key Laboratory of China Academy of Chinese Medical Sciences on Prevention and Treatment for Major Diseases, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.ORCID 0000-0001-9625-8476
Luqi HuangInstitute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ferroptosisliver fibrosisnetwork pharmacologyPPAR γproteomicsYindanpinggan Capsule

Identifiers

PMID41754793
PMCPMC12944426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.